BIOMARIN PHARMACEUTICAL INC (BMRN) Form 10-Q — Aug 6, 2026
BioMarin's Q2 2026 revenue rose about 20% year over year to $989.7 million, but net income fell to $44.8 million from $240.5 million a year ago, with diluted EPS of $0.23 versus $1.23. The quarter is the first to include the $5.3 billion acquisition of Amicus Therapeutics, completed April 27, 2026, which added GALAFOLD and POMBILITI + OPFOLDA plus U.S. rights to the Phase 3 kidney drug BMN 820; Amicus contributed $136.0 million of revenue and a $91.9 million net loss since closing.
Key figures
- Eps
- 0.23
- Revenue
- 989708000
- Net Income
- 44762000
- Total Debt
- 4250000000
- Total Assets
- 11723442000
- Cash Position
- 874005000
- Deal Value Usd
- 5323561000
- Interest Rate
- 5.5
- Maturity Date
- February 15, 2034
- Shares Outstanding
- 193573759
- Six month revenue
- 1755916000
- Variable rate debt
- 2800000000
- Goodwill from amicus
- 459164000
- Gross margin q2 2025
- 81.8%
- Gross margin q2 2026
- 79.5%
- Pro forma q2 revenue
- 1038914000
- Purchase commitments
- 854400000
- Six month net income
- 150289000
- Six month diluted eps
- 0.77
- Term loan a principal
- 800000000
- Term loan b principal
- 2000000000
- Dimerix max milestones
- 510000000
- Interest expense q2 2025
- 2700000
- Interest expense q2 2026
- 63300000
- Q2 net income prior year
- 240532000
- Q2 diluted eps prior year
- 1.23
- Intangible assets acquired
- 4750000000
- Revolving facility capacity
- 600000000
- Restructuring charges q2 2026
- 56422000
- Interest sensitivity per 100bp
- 28000000
- Operating cash flow six months
- 388760000
- Amicus revenue since acquisition
- 136006000
- Convertible notes 2027 principal
- 600000000
- Acquisition related costs q2 2026
- 30400000
Price after filing
Close on the filing date to close N calendar days later (from $60.72). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.